Search

In this study, Bi2O3/TiO2 composite was successfully synthesised using the solvothermal method, and the morphology, composition, and surface area of the composite were determined. Comparisons of photocatalytic performance were performed using Bi2O3/TiO2 for the decomposition of Atenolol (ATN) a β-blockers that is generally used to treat disorders such as hypertension and arrhythmias, as a model contaminant under visible light irradiation. The effects of different parameters such as solution pH, catalyst dosage, initial ATN concentration, reaction time, coexisting cations and anions, and turbidity on the degradation efficiency of ATN were investigated. An excellent synergistic effect was observed in the decomposition of ATN with the simultaneous application of Bi2O3/TiO2 and LED compared to single processes (synergistic index value, 4.027). The Bi2O3 catalyst has a much lower photocatalytic performance for the decomposition of ATN than the synthesised Bi2O3/TiO2 composite. The optimal rate for pH, catalyst dosage, and initial concentration of ATN was 7, 400 mg/l and 10 mg/l, respectively. Under optimal conditions, about 68.92% and 22.58% of ATN were degraded after 60 minutes in the presence of Bi2O3/TiO2 and Bi2O3 catalysts, respectively. However, these efficiencies are reduced to 51.83% and 12.4%, respectively, under 50 NTU. The addition of co-existing anions, especially PO43⁻, remarkably reduced the efficiency of ATN removal in the Bi2O3/TiO2/LED process. The presence of cations promoted the degradation of ATN in the Bi2O3/LED process, while the efficiency of ATN degradation was inhibited by the presence of cations in the Bi2O3/TiO2/LED process. The ATN removal efficiency using LED irradiation (49.02%) was much higher than that of UV-C irradiation (27.16%) when the concentration of ATN was 30 mg/L. [ABSTRACT FROM AUTHOR]

In addition to the course of over 20 years of cucurbit-7-uril (CB[7]) in the pharmaceutical industry, the present study brings together the most recent observations from the perspective of ultrasensitive Raman spectroscopy and Density Functional Theory (DFT) related to the interaction of this molecule with atenolol (Ate) enantiomers during the formation of these host–guest complexes. Quantum chemistry calculations based on DFT were first used to understand the interaction geometry between CB[7] and Ate. These results were further confirmed by ultrasensitive vibrational spectroscopy. The spectral features associated with each enantiomer in the presence of CB[7] were analyzed by means of SERS, highlighting distinct interaction profiles. These experimental findings validated quantum chemical calculations, offering a comprehensive understanding of the host–guest interactions at the nanoscale level. [ABSTRACT FROM AUTHOR]

In the present study, a modified carbon nano-onion and β–cyclodextrin composite was utilized in micro-solid phase extraction of atenolol and metoprolol from human plasma samples. The synthesized sorbent structure and morphology were evaluated. In this method, a proper amount of the sorbent was contacted with the diluted plasma sample under vortexing (to promote the sorbent contact area with the solution). The separated particles by centrifugation were contacted with a proper eluent to desorb the target analytes. After that, the eluent was separated by centrifugation and used during analysis of the analytes by high-performance liquid chromatograph. Several effective extraction parameters such as the sorbent amount, type and elution solvent volume, and extraction time were evaluated and optimized. The validated factors showed that detection and quantification were 0.09 and 0.01 and 0.29 and 0.03 ng mL–1, for metoprolol and atenolol, respectively. The method precision, considered as relative standard deviation, was ≤ 2.5 and ≤ 3.6% for intra- (n = 5) and inter-day (n = 4) precisions, respectively. The extraction recovery values were obtained 84 and 63% for metoprolol and atenolol, respectively. Lastly, the developed method was utilized successfully on the plasma samples of patients treated with metoprolol and atenolol. [ABSTRACT FROM AUTHOR]

Atenolol is a commonly used beta bloscker in non-pregnant women. Many providers are hesitant in prescribing atenolol in pregnancy because of a possible association with poor fetal growth. We aimed to assess the association between atenolol and the occurrence of small for gestational age neonates compared to other beta blockers, as described in the existing literature. We used the meta-analytic method to generate a forest plot for risk ratios (RR) of small for gestational age in patients who used atenolol vs. other beta blockers. Statistical heterogeneity was assessed with the I2 statistic. Two studies were included, with a resultant RR of 1.94 [95 % confidence interval (CI) 1.60; 2.35]. A study by Duan et al. in 2018 noted the following rate of small for gestational age for each beta blocker use: 112/638 atenolol, 590/3,357 labetalol, 35/324 metoprolol, and 50/489 propranolol. A study by Tanaka et al. in 2016 noted the following rate of small for gestational age: 8/22 for propranolol, 2/12 for metoprolol, 2/6 for atenolol, 0/5 for bisoprolol. Heterogeneity (I2) was 0 %. Our results suggested an elevated risk of small for gestational age associated with atenolol use in comparison to other beta blockers, specifically labetalol, propranolol, bisoprolol, and metoprolol. [ABSTRACT FROM AUTHOR]

Enantioselective separation of atenolol (ATL) enantiomers employing carboxymethyl-β-cyclodextrin as chiral selector has been reported in a limited number of studies. However, none of these experimental works achieved enantiomer assignment, precluding the elucidation of the enantiomeric migration order (EMO). In this sense, to elucidate for the first time the fundamental principles governing the enantioselective recognition of atenolol enantiomers, we conducted a comprehensive theoretical study of the formation mechanisms of their inclusion complexes. As main result, based on structural, electronic, and energetic properties, we were able to indicate that (-)-(S)-ATL is anticipated to exhibit a prolonged migration time compared to (+)-(R)-ATL. This differential migration behavior stems from the stronger interaction between (-)-(S)-ATL and the chiral selector, resulting in a more stable inclusion complex and consequently, enhanced retention. These findings highlight the remarkable potential of molecular modeling techniques in deepening our understanding of enantioseparation mechanisms. [ABSTRACT FROM AUTHOR]

Abstract Objectives The objective of this study is to investigate the association between the use of beta‐adrenergic antagonist atenolol and risk of pathologic upgrade in patients on active surveillance, considering growing literature implicating adrenergic innervation with disease progression mediated through beta‐adrenergic signalling. Patients and Methods Men with low‐risk or favourable intermediate‐risk prostate cancer who were placed on an active surveillance protocol between 2006 and 2020 across three diverse urban hospitals were included. Exposure was duration of atenolol use, and outcome was pathologic grade group upgrading (to GG ≥ 3) on final prostate biopsy. Cox proportional hazard regression models were used to determine the associations between atenolol use and risk of upgrading with time, on a per‐examination basis. Results A total of 467 men with initial GG ≤ 2 were included. Postdiagnosis atenolol use was associated with a decreased risk of pathologic upgrade to GG ≥ 3 on final repeat biopsy (HR 0.81, 95% CI 0.39–0.98). Longer duration of postdiagnosis atenolol use (>2 years) and greater cumulative atenolol dose (>730 defined daily doses) were associated with a more pronounced decreased risk of upgrade to GG ≥ 3 (HR 0.41, 95% CI 0.05–0.88, and HR 0.32, 95% CI 0.15–0.99, respectively). Initiation of atenolol use prior to prostate cancer diagnosis had a slightly greater protective effect than drug initiation postdiagnosis (HR 0.79, 95% CI 0.43–0.98, and HR 0.83, 95% CI 0.30–0.99, respectively). Conclusions Beta‐adrenergic blockade with atenolol use in men on active surveillance is associated with a reduced risk for clinically significant grade group pathologic upgrade.

Hypertension alters tooth formation and Atenolol reduces the blood pressure of spontaneously hypertensive rats (SHR) during pregnancy and lactation, and as demonstrated before, increases the microhardness of the SHR offspring’s teeth. MMP-9 is overexpressed in different tissues of hypertensive animals and treatment of hypertension substances can reverse this alteration. We hypothesize hypertension alters the expression of MMP-9 in dental structures of SHR offspring and that treating female SHR with atenolol prevents this alteration. This study aimed to evaluate the expression of matrix metalloproteinase (MMP-9) in incisor teeth (IT) in male offspring of SHR (30 days old) treated or untreated with Atenolol during pregnancy and lactation. MMP-9 expression was evaluated in ameloblasts (AM), enamel matrix (EM), odontoblasts (OD), and predentin (PD) of IT through immunohistochemical reactions (immunoperoxidase). Data were analyzed by Shapiro-Wilk and Kruskal-Wallis (p < 0.05), with Dunn post-test. Histological differences were not observed between IT tissues of SHR and normotensive Wistar rats. For the first time, our data showed that MMP-9 expression in specific dental structures is not altered in SHR. Atenolol treatment increased MMP-9 immunostaining in EM of Wistar rat, however, Atenolol did not alter MMP-9 in the IT tissues of SHR. Our results demonstrated that MMP-9 expression in dental tissues is not affected by hypertension or atenolol treatment in dental tissues. If confirmed in humans, the results obtained in this study will corroborate the suggestion that MMP-9 is not a viable therapeutic target for the treatment of dental alterations associated with maternal hypertension. [ABSTRACT FROM AUTHOR]

Background: Active drugs and nutraceutical supplements commonly induce various gastrointestinal illnesses, and constipation is a major gastrointestinal symptom accompanied with functional gastrointestinal disorders. Drug-induced imbalance in gut microbiota may play critical role in such physiological disturbances. Probiotics have been known for resuming normal and healthy gut microbiome. Objective: To investigate the clinical efficacy and safety of Bacillus coagulans LBSC in the treatment of drug induced constipation associated with functional gastrointestinal disorder (FGID) symptoms. Methods: A prospective, interventional, randomized, double-blind, parallel, multi-arm, controlled trial with 168 patients experiencing drug induced constipation associated with FGID symptoms (DICAWFGID) screened through Rome IV criteria were randomized into 2 arms, i.e. placebo arm (n = 28) and atorvastatin, atenolol, metformin, amitriptyline, and calcium in test arm (n = 28/arm). Patients in both arms received similar dosages (1 g sachet, 3 times a day) for 35 days. The occurrence of constipation using Bristol Stool Form Scale, assessment of degree of constipation on 4-point Likert scale, occurrence of hard stool and degree of stool expulsion on 3-point scale, and defecation frequency were primary endpoints. While, secondary outcomes consisted of the changes in severity of FGID symptoms, visual analogue scale and tolerance to IP, along with reports of adverse events (AEs) and severe adverse events (SAEs). Results: There was a significant reduction in occurrence of constipation (≥98.6% and P -value <0.05) in test arm over the placebo arm. Assessment of co-primary endpoints showed significant improvements in degree of stool consistency (P -value 0.0232; CI: 0.1870, 1.1629), borderline significantly superior in degree of stool expulsion (P -value 0.0553; CI: 0.0378, −0.4939), while the other co-primary efficacy endpoints displayed considerably improved advancement (non-significant, P -value ≥0.05). The intra group analysis of symptoms at start of treatment (SOT) and end of treatment (EOT) revealed a significant reduction in scores for occurrence of constipation and degree of constipation, whereas significant improvement in the scores for degree of stool consistency and degree of stool expulsion (P -value <0.001) after the intervention period. In secondary endpoints, the processed responses clearly signified a considerable positive improvement (non-significant, P -value ≥0.05) in other symptoms of constipation associated with FGIDs as determined by the changes in the EOT-SOT score. The study data also highlighted the safety o f Bacillus coagulans LBSC at the studied dose. No AEs and/or SAEs were documented during the investigation. Conclusion: At the studied dose, Bacillus coagulans LBSC was safe for oral consumption and effective in the management of the drug induced constipation associated with FGIDs symptoms. [ABSTRACT FROM AUTHOR]

In this study, the appropriate polymer solutions were prepared to create chitosan/PVA blends. By altering the ratio of the ingredients, several chitosan/PVA mixtures were produced, as follows: 12% chitosan and 88% PVA, 40% chitosan and 60% PVA, and 15% chitosan and 85% PVA. To generate physically crosslinked hydrogels for the drug delivery of atenolol, several acid cross-linkers, such as fumaric acid and phthalic acid, were applied to the chitosan/PVA blends. The formulations included 15% chitosan and 85% PVA with 0.02% (0.0024, 0.0041, 0.02) mol of fumaric acid, as well as 15% chitosan and 85% PVA with 0.002, 0.003, and 0.0064 mol of phthalic acid. Using an ultraviolet-visible spectrophotometer, the chemical structures of the modified and unmodified chitosan (Chitosan/PVA) hydrogels were examined. Results regarding the formation of ionic cross-links between the protonated hydroxyl groups of the chitosan and the anionic functional groups of the cross-linking agent were established. The swelling ratio was determined for each hydrogel structure as a function of time in three distinct fluids with pH values of 2, 4, and 7.5, and at three distinct temperatures of 42°C and 44°C. The samples with the greatest swelling ratios were identified as PVA.PA0.002 (chitosan) and PVA.FA0.0024. [ABSTRACT FROM AUTHOR]

We describe the clinical presentation and evaluation of a 10-year-old boy who presented to our medical center with years of progressive proximal muscle weakness, muscle atrophy, and weight loss. In addition to a myopathic phenotype, he was found to have tachycardia, tremor, and learning difficulties. Electromyography revealed chronic myopathic changes and laboratory screening was notable for undetectable thyroid stimulating hormone. Follow-up testing revealed elevated thyroid peroxidase antibodies and thyroid stimulating immunoglobulins. Ultrasound examination revealed an enlarged heterogeneous thyroid gland. Four weeks after treatment with atenolol and methimazole, his strength and cognition began to improve. This case highlights the importance of evaluating for potentially reversible toxic-metabolic etiologies in children presenting with any progressive neurologic symptoms. [ABSTRACT FROM AUTHOR]

The preferential solvation parameters of atenolol in aqueous binary mixtures of propylene glycol (PG) were derived from reported molar solubility values after conversion to mole fractions by using the inverse Kirkwood–Buff integrals method. This drug is sensitive to preferential solvation effects in this binary system. The preferential solvation parameter by PG (δx1,3) is negative in water-rich mixtures but positive in mixtures of 0.20 < x1 < 1.00. It is conjecturable that hydrophobic hydration around the non-polar methyl and phenylene groups of this drug observable in water-rich mixtures could play a relevant role in drug solvation. Otherwise, in mixtures of 0.20 < x1 < 1.00, the preferential solvation by PG could be due to the acidic behaviour of atenolol. [ABSTRACT FROM AUTHOR]

Atenolol, a cardioselective β1‐blocker, exhibits efficacy in treating cardiovascular diseases. We conducted a single‐center, randomized, open, single‐dose, 2‐preparation, 2‐cycle, 2‐sequence, double‐crossover trial with a 7‐day washout period to investigate the pharmacokinetics, bioequivalence (BE), and safety of test and reference atenolol tablets (25 mg) in healthy Chinese volunteers. Forty‐eight healthy participants were randomized into the fasting and fed arms. After administering a single oral dose of the test or reference formulation (25 mg), plasma atenolol concentrations were measured using liquid chromatography‐tandem mass spectrometry. Pharmacokinetic parameters were obtained from concentration‐time profiles. In total, 23 and 24 individuals were included in the fasting and fed arms, respectively. The mean concentration‐time profiles for both formulations were similar, and Cmax, AUC0‐t, and AUC0‐∞ were within the BE range of 80%‐125%. Thirteen adverse events (AEs) were observed in 7 participants in the fasting arm; 1 withdrew from the trial early owing to an AE. In the fed arm, 20 AEs were observed in 8 participants, and none withdrew from the trial. All adverse reactions were grade I, with no serious AEs or deaths. Therefore, the 2 tablets are bioequivalent in healthy Chinese individuals under fasting and fed conditions, supporting their further clinical development. [ABSTRACT FROM AUTHOR]

The limited availability of pharmaceutical formulations tailored for cardiovascular diseases in both pediatric and geriatric populations generates the need for compounded dosage forms to guarantee precise dosing and medication adherence. This study aimed to analyze the physicochemical properties and stability of formulations of atenolol and enalapril maleate prepared with a proprietary oral vehicle, SuspendIt®. To this end, palatability, injectability, pH, rheological behavior, and physical, microbiological, and chemical stability over a 180-day storage period at 25 °C and 5 °C were evaluated. Injectability tests confirmed the suitable use of both formulations for administration through enteral feeding tubes. By using a potentiometric electronic tongue, it was confirmed that the SuspendIt® vehicle effectively served as a bitter-blocking strategy for atenolol and enalapril maleate. Adequate stability throughout the storage period was confirmed in terms of the mechanical properties, pH, and effectiveness of the preservative system. The atenolol concentration remained above 90% of the initial amount, while the concentration of enalapril maleate decreased to 88% after 90 days of storage at 25 °C. In summary, the atenolol formulation maintained suitable chemical, physical, and microbiological stability after 180 days at both storage temperatures, while the enalapril maleate formulation remained stable up to 60 days at 25 °C and for 180 days at 5 °C. [ABSTRACT FROM AUTHOR]

Environmental contamination by pharmaceuticals from industrial waste and anthropogenic activities poses adverse health effects on non-target organisms. We evaluated the neurobehavioral and biochemical responses accompanying exposure to ecological relevant concentrations of atenolol (0, 0.1, 1.0, and 10 µg/L) for seven uninterrupted days in adult zebrafish (Danio rerio). Atenolol-exposed fish exhibited anxiety-like behavior, characterized by significant bottom-dwelling with marked reduction in vertical exploration. Atenolol-exposed fish exhibited marked increase in the duration and frequency of aggressive events without altering their preference for conspecifics. Biochemical data using brain samples indicated that atenolol disrupted antioxidant enzyme activities and induced oxidative stress. Exposure to atenolol markedly decreased ATP and AMP hydrolysis without affecting ADP hydrolysis and acetylcholinesterase (AChE) activity. Atenolol significantly upregulated tryptophan hydroxylase 1 (tph1) mRNA expression but downregulated brain-derived neurotrophic factor (bdnf) mRNA. Collectively, waterborne atenolol elicits aggressive and anxiety-like responses in adult zebrafish, accompanied by oxidative stress, reduced nucleotide hydrolysis, altered tph1 and bdnf mRNA expression, which may impact the survival and health of fish in aquatic environment. [ABSTRACT FROM AUTHOR]

Objectives: Hypertension is one of the major modifiable risk factors for cardiovascular mortality and morbidity throughout the world. Increased life expectancy leads to increase prevalence of non‐communicable diseases among the elderly people including Bangladesh. However, different studies reported high prevalence of uncontrolled hypertension ranging from 52.6% to 67.9% among the elderly people in different countries. With this view, we aimed to assess the frequency of uncontrolled blood pressure (BP) among the elderly hypertensive people and its associated risk factors and treatment pattern in Bangladesh. Methodology: This cross‐sectional type of observational study recruited 246 eligible hypertensive elderly patients attending in 250 Bedded General Hospital, Jashore, Bangladesh dated from 1st July to 31st December 2022. A structured questionnaire was developed and data on associated risk factors, treatment pattern and current blood pressure (BP) measurement were collected by face‐to‐face interview for the purposive sampling technique. Results: The mean age of our study patients was 72 ± 7 years with a male and female ratio nearly 1:1. Of the total hypertensive patients aged over 65 years or more, 56.5% remained with uncontrolled hypertension even on their prescribed antihypertensive medications. The mean systolic (SBP) and diastolic (DBP) blood pressure were significantly high (P < 0.001) as 167 ± 22 mm Hg and 95 ± 11 mm Hg, respectively, among the uncontrolled hypertensive patients. However, we noticed the mean SBP and DBP among the total hypertensive patients were also significantly high (P < 0.001) as 148 ± 27 mm Hg and 87 ± 13 mm Hg, respectively. In this study, we reported that the mean number of last prescribed antihypertensive medications used by the total patients was 2 ± 1 (P =0.224) which was similar among the controlled and uncontrolled hypertensive patient groups. Among the elderly hypertensive patients, the most commonly prescribed antihypertensive medications were Amlodipine 39.8% (P =0.006), Olmesartan 29.3% (P = 0.186), Losartan 24.4% (P = 0.127), Bisoprolol 15.0% (P = 0.266) and Atenolol 14.6% (P = 0.224). Conclusion: We noticed high frequency of uncontrolled blood pressure among the elderly hypertensive patients, despite of using multiple antihypertensive medications in Jashore, Bangladesh. [ABSTRACT FROM AUTHOR]

Objective: Unusual clinical course. Background: Amlodipine, a calcium channel blocker, and atenolol, a beta blocker, are commonly used as a fixed drug combination (FDC) to treat hypertension. Intentional or non-intentional overdose of amlodipine-atenolol results in hypotension and myocardial depression with a high risk of mortality. This report describes a 64-year-old man with an overdose of amlodipine-atenolol, presenting as an emergency with hypotension, bradycardia, and severe metabolic acidosis. He was successfully treated with intravenous calcium chloride infusion, hyperinsulinemia euglycemia therapy (HIE), and continuous veno-venous hemodialysis (CVVHD). Case Report: A 64-year-old man was diagnosed with essential hypertension 1 week prior to the admission. He had been prescribed 1 FDC tablet of amlodipine and atenolol (5+50 mg) per day; however, he took 1 table of the FDC per day for 3 days and then took 3-4 tablets each day during the next 4 days. He was brought to the hospital with hypotension, bradycardia, and severe metabolic acidosis and was diagnosed with amlodipine-atenolol overdose. He was treated with intravenous calcium chloride infusion, HIE, and CVVHD. His hemodynamics started to improve after administering these therapies for 6 h. Inotropes were gradually tapered off and stopped. He was extubated on day 5 and recovered completely. Conclusions: This report shows the serious effects amlodipine-atenolol overdose and the challenges of emergency patient management. An overdose of FDC of amlodipine and atenolol can cause cardiovascular collapse and severe metabolic acidosis. Timely and aggressive management with intravenous calcium infusion, HIE, and CVVHD is essential. [ABSTRACT FROM AUTHOR]

This paper demonstrates the synthesis and storage of molecular-imprinted polymers (MIP) at room temperature using bulk polymerization of atenolol (Ate), which is characterized by high sensitivity, low costs, and high stability. The research used 0.99:6:20 mmol ratios of template, monomer, and cross-linking agents for the polymerization in order to ensure an appropriate adsorption capacity. By making MIP for atenolol as Ate-MIP, which could be looked at with a UV-VIS spectrophotometer at 276 nm, Fourier- transform infrared spectroscopy (FT-IR), and scanning electron microscopy (SEM), a functional monomer of allyl chloride with cross-linking ethylene glycol dimethyl acrylate was made. Mass spectrometric (MS) detection may use allyl chloride to determine atenolol levels in pharmaceutical preparations. The GC/MS methods developed in this study are accurate, sensitive, and precise and can be easily applied to (NOVATEN/India and ATENOIOI/U.K.) tablets in pharmaceutical preparation. The elution process was applied to the template (Ate) from the Ate-MIP, which developed cavities, caused by using porogenic solutions of methanol, chloroform, and acetic acid (70:20:10, respectively). The maximum adsorption capacity of Ate-MIP was 2.9957 µmol/g, and the ratio of template to monomer was 1:1 in adherence to the Langmuir isotherm model. A solid-phase extraction (SPE) syringe packed with molecular imprinted polymers (MIPs) was used to selectively separate and pre-concentrate Ate from aqueous solutions and estimations of atenolol. [ABSTRACT FROM AUTHOR]

Pharmaceuticals and drugs of abuse are organic micropollutants of emerging concern in both surface and groundwater worldwide. These compounds are considered to be pseudo‐persistent because of their continuous release into water systems. The presence of these compounds in the environment at any concentration poses a potential risk to nontarget organisms. The main sources of these contaminants are wastewater treatment plants (WWTPs) and combined sewer overflows (CSOs). The primary goal of our study was to identify and quantify a panel of 28 commonly prescribed pharmaceuticals (mood‐altering drugs, cardiovascular drugs, antacids, antibiotics) and high‐prevalence drugs of abuse (cocaine, amphetamines, opioids, cannabis) in river water samples collected from 19 locations in the Hudson and East rivers in New York City. The second goal was to investigate the possible source (WWTP or CSOs) of these micropollutants. Samples were collected weekly from May to August 2021 (n = 224) and May to August 2022 (n = 232), and placed at −20 °C until analysis by liquid chromatography–tandem mass spectrometry. The most frequently detected analytes in 2021 were metoprolol (n = 206, 92%), benzoylecgonine (n = 151, 67%), atenolol (n = 142, 63%), and methamphetamine (n = 118, 53%), and in 2022 the most frequently detected were methamphetamine (n = 194, 84%), atenolol (n = 177, 76%), metoprolol (n = 177, 76%), and 2‐ethylene‐1,5‐dimethyl‐3,3‐diphenylpyrrolidine (n = 159, 69%). Measured concentrations ranged from the limit of detection (0.50–5.00 ng/L) to 103 ng/L. More drugs and higher concentrations were detected in water contaminated by Enterococci (>60 most probably number) and after rainfall, indicating the influence of CSOs. The presence of drugs in samples with little to no Enterococci and after dry weather events indicates that WWTPs contribute to the presence of these substances in the river, probably due to a low removal rate. Environ Toxicol Chem 2024;43:1592–1603. © 2024 SETAC [ABSTRACT FROM AUTHOR]

Aim: Using atenolol as a model active pharmaceutical and galactomannan from the seeds of Trigonella foenumgraecum as a mucoadhesive polymer, an effort was made to develop a gastroretentive bioadhesive floating delivery system to improve the residence time in the stomach. Materials and Methods: Different formulations were made with Hydroxypropyl Methyl Cellulose (HPMC) and galactomannan. Galactomannan was chosen because of its exceptional swelling properties in aqueous environments. In this investigation, citric acid and sodium bicarbonate were utilized as gas-producing components. Pre- and postcompression evaluations were performed on the manufactured tablets. The floating properties as well as the atenolol release pattern were investigated. Results: The extracted polymer was characterized using various techniques and found to be similar to literature. The results from GC analysis showed a residual acetone content of 0.127 ppm, indicating that the extracted polymer is safer to use in the formulation of gastroretentive tablets. The physicochemical properties of the manufactured tablets were satisfactory in terms of swelling index, release characteristics, and buoyancy pattern. All of the manufactured batches had adequate in vitro buoyancy. The gastroretentive tablet exhibited axial and radial swelling throughout the in vitro buoyancy test. According to the testing, the formulation remained buoyant for approximately 8 to 12 hr. Conclusion: According to the results of the evaluation, the manufactured tablet has a pleasing look, is heat stable, and is therapeutically efficient. F3 was determined to be the optimal formulation based on the data collected. [ABSTRACT FROM AUTHOR]

A green, sensitive, and fast spectrofluorimetric technique for the simultaneous determination of atenolol (ATN) and losartan potassium (LSR) was developed. The proposed technique relied on the implementation of a first derivative synchronous fluorescence spectroscopy for the determination of the investigated drugs simultaneously without pretreatment procedures. The synchronous fluorescence of both drugs was measured in methanol at Δλ of 100 nm, and the first derivative peak amplitudes (1D) were measured at 321 nm for ATN and 348 nm for LSR, each at the zero‐crossing point of the other. The method was rectilinear over the concentration ranges of 100–1000 ng/mL and 50–500 ng/mL for ATN and LSR, respectively. The proposed technique was successfully applied for the determination of the studied drugs in their laboratory‐prepared mixture and pharmaceutical formulations, demonstrating high mean recoveries of 100.54% for ATN and 100.62% for LSR, without interference from common excipients. The results were in good agreement with those obtained by the comparison method. Three recent greenness assessment tools, the Eco‐Scale tool, the Green Analytical Procedure Index (GAPI) metric, and the Analytical GREEnness metric approach, were employed to affirm the greenness of the proposed method. The developed method was proven to be eco‐friendly. [ABSTRACT FROM AUTHOR]

Objective: To develop a Raman spectroscopy-based analytical model for quantification of solid dosage forms of active pharmaceutical ingredient (API) of Atenolol. Significance: For the quantitative analysis of pharmaceutical drugs, Raman Spectroscopy is a reliable and fast detection method. As part of this study, Raman Spectroscopy is explored for the quantitative analysis of different concentrations of Atenolol. Methods: Various solid-dosage forms of Atenolol were prepared by mixing API with excipients to form different solid-dosage formulations of Atenolol. Multivariate data analysis techniques, such as Principal Component Analysis (PCA) and Partial least square regression (PLSR) were used for the qualitative and quantitative analysis, respectively. Results: As the concentration of the drug increased in formulation, the peak intensities of the distinctive Raman spectral characteristics associated with the API (Atenolol) gradually increased. Raman spectral data sets were classified using PCA due to their distinctive spectral characteristics. Additionally, a prediction model was built using PLSR analysis to assess the quantitative relationship between various API (Atenolol) concentrations and spectral features. With a goodness of fit value of 0.99, the root mean square errors of calibration (RMSEC) and prediction (RMSEP) were determined to be 1.0036 and 2.83 mg, respectively. The API content in the blind/unknown Atenolol formulation was determined as well using the PLSR model. Conclusions: Based on these results, Raman spectroscopy may be used to quickly and accurately analyze pharmaceutical samples and for their quantitative determination. [ABSTRACT FROM AUTHOR]

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a primary electrical heart disease characterized by the development of polymorphic (including bidirectional) ventricular tachycardia in response to adrenergic stimulation. The leading clinical sign of CPVT is syncope provoked by physical or emotional stress, or adrenergic drugs administration. This disease is characterized by high mortality if not treated. The main treatment approach for CPVT is drug therapy with beta-blockers. Recently, however, there are more and more works stating that beta-blockers have lack of efficacy. Combination therapy with the antiarrhythmic drug of the IC class is one of the approaches before implementing the interventional treatment methods in several patients. Interventional methods include cardioverter defibrillator implantation and left side sympathectomy. This paper presents the modern view on the efficacy, safety, and indications for every management method for patients with CPVT.

Abstract Background Despite several justifications for utilizing beta-blockers, such as atenolol, as the initial treatment for hypertension in the presence of cardiovascular disease, some studies have demonstrated that calcium channel blockers were more effective than beta-blockers in decreasing mortality. This review intended to determine the efficacy of atenolol in reducing all-cause mortality in Asian individuals with hypertension, coronary artery disease, atrial fibrillation, and heart failure. Main body of the abstract Studies published before March 31, 2023, were searched using Trip, Google Scholar, Cochrane, and EMBASE databases. We only considered studies that compared atenolol with other medications in terms of all-cause mortality rates in Asian individuals diagnosed with hypertension and cardiovascular diseases. Therefore, we only considered three trials with a total of 79,603 participants. The results indicated a statistically significant higher all-cause death rate among non-atenolol users compared to atenolol users (p

Atenolol (ATE) and propranolol (PRO) inclusion complexes with β-cyclodextrin have been investigated in aqueous solution. The aqueous solution was examined and characterized using UV–vis, fluorescence spectroscopy, and 1H NMR. The physical mixture was characterized using FTIR. The existence of inclusion complexes is confirmed by observing changes in spectroscopic properties. The ATE complex with β-CD exhibited an interaction as host and (β-CD) as a guest in a 1:1 ratio, with an inclusion constant K of 2.09 × 10−3 µM−1, as determined by the typical double-reciprocal graphs. Similarly, the PRO complex with β-CD exhibited an interaction as host and (β-CD) guest in 1:1 and 1:2 stoichiometry at the same time; the inclusion constants were K1 = 5.80 × 10−5 µM−1 and K2 = 4.67 × 10−8 µM−1, as determined by typical double-reciprocal graphs. The variables influencing the formation of the inclusion complexes were investigated and optimized. Based on the enhancement in fluorescence intensity due to the formation of inclusion complexes, spectrofluorometric methods were developed and validated for determination of each drug's pharmaceutical formulation. The quantification of the fluorescence intensity for ATE and PRO was conducted at λex/λem 226/302 nm and λex/λem 231/338 nm, respectively. Under the optimal reaction circumstances, linear relationships with good correlation coefficients of 0.9918 and 0.99 were found in the concentration ranges of 0.3–1.7 μM, and 0.1–1.1 μM for ATE and PRO, respectively. The limits of detection (LODs) were found to be 0.13 and 0.01 μM for ATE and PRO, respectively. The suggested approach was effectively applied to the analysis of both drugs' pharmaceutical formulations. [ABSTRACT FROM AUTHOR]

Atenolol, one of the top five best-selling drugs in the world today used to treat angina and hypertension, and to reduce the risk of death after a heart attack, faces challenges in current synthetic methods to address inefficiencies and environmental concerns. The traditional synthesis of this drug involves a process that generates a large amount of waste and other by-products that need disposal. This study presents a one-pot DES-based sustainable protocol for synthesizing atenolol. The use of the DES allowed the entire process to be conducted with no need for additional bases or catalysts, in short reaction times, under mild conditions, and avoiding chromatographic purification. The overall yield of atenolol was 95%. The scalability of the process to gram-scale production was successfully demonstrated, emphasizing its potential in industrial applications. Finally, the 'greenness' evaluation, performed using the First Pass CHEM21 Metrics Toolkit, highlighted the superiority in terms of the atom economy, the reaction mass efficiency, and the overall process mass intensity of the DES-based synthesis compared with the already existing methods. [ABSTRACT FROM AUTHOR]

Developing the Co-based catalysts with high reactivity for the sulfate radical (SO4−·)–based advanced oxidation processes (SR-AOPs) has been attracting numerous attentions. To improve the peroxymonosulfate (PMS) activation process, a novel Co-based catalyst simultaneously modified by bamboo carbon (BC) and vanadium (V@CoO-BC) was fabricated through a simple solvothermal method. The atenolol (ATL) degradation experiments in V@CoO-BC/PMS system showed that the obtained V@CoO-BC exhibited much higher performance on PMS activation than pure CoO, and the V@CoO-BC/PMS system could fully degrade ATL within 5 min via the destruction of both radicals (SO4−· and O2−··) and non-radicals (1O2). The quenching experiments and electrochemical tests revealed that the enhancing mechanism of bamboo carbon and V modification involved four aspects: (i) promoting the PMS and Co ion adsorption on the surface of V@CoO-BC; (ii) enhancing the electron transfer efficiency between V@CoO-BC and PMS; (iii) activating PMS with V3+ species; (iv) accelerating the circulation of Co2+ and Co3+, leading to the enhanced yield of reactive oxygen species (ROS). Furthermore, the V@CoO-BC/PMS system also exhibited satisfactory stability under broad pH (3–9) and good efficiency in the presence of co-existing components (HCO3−, NO3−, Cl−, and HA) in water. This study provides new insights to designing high-performance, environment-friendly bimetal catalysts and some basis for the remediation of antibiotic contaminants with SR-AOPs. [ABSTRACT FROM AUTHOR]

Atenolol β‐blocker drug (ATN) to treat hypertension and cardiovascular disorders such as angina pectoris is manufactured commercially in a racemic form, while only its (S)‐enantiomer shows selective β1‐blocking activity. Here, a new axially chiral thiolated naphthalene diimide derivatives (HS‐BIN‐NDI) for the rapid, simple, and sensitive detection of ATN enantiomers is presented. The Surface Plasmon Resonance (SPR) and Atomic Force Microscopy (AFM) experiments show that interactions between a chiral selector and a chiral analyte occur only when their configurations are opposite. The extensive computational simulations support this finding. The association coefficient determined by SPR is high (105‐106 M−1 s−1) and indicates that the interactions are electrostatic. The analytical utility of atropisomeric HS‐BIN‐NDIs is proven, and the voltammetric sensors designed to determine ATN enantiomers are constructed. The developed sensors are characterized by a wide analytical operating range from 5.0·10−3 to 1.0 µm, nanomolar detection limit, high selectivity, and a long lifetime. Several additives like urea, creatinine, glucose, human albumin, and hemoglobin do not affect ATN sensing. [ABSTRACT FROM AUTHOR]

Background: Despite several justifications for utilizing beta-blockers, such as atenolol, as the initial treatment for hypertension in the presence of cardiovascular disease, some studies have demonstrated that calcium channel blockers were more effective than beta-blockers in decreasing mortality. This review intended to determine the efficacy of atenolol in reducing all-cause mortality in Asian individuals with hypertension, coronary artery disease, atrial fibrillation, and heart failure. Studies published before March 31, 2023, were searched using Trip, Google Scholar, Cochrane, and EMBASE databases. We only considered studies that compared atenolol with other medications in terms of all-cause mortality rates in Asian individuals diagnosed with hypertension and cardiovascular diseases. Therefore, we only considered three trials with a total of 79,603 participants. The results indicated a statistically significant higher all-cause death rate among non-atenolol users compared to atenolol users (p < 0.001). The all-cause death rate was considerably greater in individuals who consumed metoprolol tartrate compared to those who consumed atenolol (OR = 0.50, p < 0.0001). Although the included publications were deemed to have a low risk of bias, significant heterogeneity was observed (p = 0.001). Short conclusion: Due to the limited studies included, this analysis concluded that atenolol, in comparison with non-users of atenolol or especially metoprolol tartrate, significantly reduces the overall death rate in East Asian and Southeast Asian patients with hypertension, coronary artery disease, atrial fibrillation, and heart failure. Yet, the current study cannot finalize this conclusion for other Asian ethnic groups, such as South Asians, Central Asians, and West Asians. Additional systematic reviews and meta-analyses with low heterogeneity and high-quality evidence are suggested to validate our findings and explore the efficacy of atenolol in various ethnic populations. [ABSTRACT FROM AUTHOR]

Drug-induced convulsions are a major challenge to drug development because of the lack of reliable biomarkers. Using machine learning, our previous research indicated the potential use of an index derived from heart rate variability (HRV) analysis in non-human primates as a biomarker for convulsions induced by GABAA receptor antagonists. The present study aimed to explore the application of this methodology to other convulsants and evaluate its specificity by testing non-convulsants that affect the autonomic nervous system. Telemetry-implanted males were administered various convulsants (4-aminopyridine, bupropion, kainic acid, and ranolazine) at different doses. Electrocardiogram data gathered during the pre-dose period were employed as training data, and the convulsive potential was evaluated using HRV and multivariate statistical process control. Our findings show that the Q-statistic-derived convulsive index for 4-aminopyridine increased at doses lower than that of the convulsive dose. Increases were also observed for kainic acid and ranolazine at convulsive doses, whereas bupropion did not change the index up to the highest dose (1/3 of the convulsive dose). When the same analysis was applied to nonconvulsants (atropine, atenolol, and clonidine), an increase in the index was noted. Thus, the index elevation appeared to correlate with or even predict alterations in autonomic nerve activity indices, implying that this method might be regarded as a sensitive index to fluctuations within the autonomic nervous system. Despite potential false positives, this methodology offers valuable insights into predicting druginduced convulsions when the pharmacological profile is used to carefully choose a compound. [ABSTRACT FROM AUTHOR]

This study aims to explore the impact of ADME on the Oral Bioavailability (OB) of drugs and to construct a machine learning model for OB prediction. The model is then applied to predict the OB of modified berberine and atenolol molecules to obtain structures with higher OB. Initially, a drug OB database was established, and corresponding ADME characteristics were obtained. The relationship between ADME and OB was analyzed using machine learning, with Morgan fingerprints serving as molecular descriptors. Compounds from the database were input into Random Forest, XGBoost, CatBoost, and LightGBM machine learning models to train the OB 7prediction model and evaluate its performance. Subsequently, berberine and atenolol were modified using Chemdraw software with ten different substituents for mono-substitution, and chlorine atoms for a full range of double substitutions. The modified molecular structures were converted into the same format as the training set for OB prediction. The predicted OB values of the modified structures of berberine and atenolol were compared. An OB database of 386 drugs was obtained. It was found that smaller molecular weight and a higher number of rotatable bonds (ten or less) could potentially lead to higher OB. The four machine learning models were evaluated using MSE, R2 score, MAE, and MFE as metrics, with Random Forest performing the best. The models' predictions for the test set were particularly accurate when OB ranged from 30% to 90%. After mono-substitution and double substitution of berberine and atenolol, the OB of both drugs was significantly improved. This study found that some ADME properties of molecules do not have an absolute impact on OB. The database played a decisive role in the process of the machine learning OB prediction model, and the performance of the model was evaluated based on predictions within a range of strong generalization ability. In most cases, mono-substitution and double substitution were beneficial for enhancing the OB of berberine and atenolol. In summary, this study successfully constructed a machine learning regression prediction model that can accurately predict drug OB, which can guide drug design to achieve higher OB to some extent. [ABSTRACT FROM AUTHOR]

Introduction Evidence is mounting that electronic cigarette (e-cig) use induces cardiac sympathetic dominance and electrical dysfunction conducive to arrhythmias and dependent upon nicotine. A variety of nicotine types and concentrations are available in e-cigs, but their relative cardiovascular effects remain unclear. Here we examine how different nicotine forms (racemic, free base, and salt) and concentrations influence e-cig-evoked cardiac dysfunction and arrhythmogenesis and provide a mechanism for nicotine-salt-induced autonomic imbalance. Methods ECG-telemetered C57BL/6J mice were exposed to filtered air (FA) or e-cig aerosols from propylene glycol and vegetable glycerin solvents either without nicotine (vehicle) or with increasing nicotine concentrations (1%, 2.5%, and 5%) for three 9-minute puff sessions per concentration. Spontaneous ventricular premature beat (VPB) incidence rates, heart rate, and heart rate variability (HRV) were compared between treatments. Subsequently, to test the role of β1-adrenergic activation in e-cig-induced cardiac effects, mice were pretreated with atenolol and exposed to either FA or 2.5% nicotine salt. Results During puffing and washout phases, ≥2.5% racemic nicotine reduced heart rate and increased HRV relative to FA and vehicle controls, indicating parasympathetic dominance. Relative to both controls, 5% nicotine salt elevated heart rate and decreased HRV during washout, suggesting sympathetic dominance, and also increased VPB frequency. Atenolol abolished e-cig-induced elevations in heart rate and declines in HRV during washout, indicating e-cig-evoked sympathetic dominance is mediated by β1-adrenergic stimulation. Conclusions Our findings suggest that inhalation of e-cig aerosols from nicotine-salt-containing e-liquids could increase the cardiovascular risks of vaping by inducing sympathetic dominance and cardiac arrhythmias. Implications Exposure to e-cig aerosols containing commercially relevant concentrations of nicotine salts may increase nicotine delivery and impair cardiac function by eliciting β1-adrenoceptor-mediated sympathoexcitation and provoking ventricular arrhythmias. If confirmed in humans, our work suggests that regulatory targeting of nicotine salts through minimum pH standards or limits on acid additives in e-liquids may mitigate the public health risks of vaping. [ABSTRACT FROM AUTHOR]

Two simple and rapid ultraviolet spectrophotometric methods were developed to estimate indapamide and atenolol in marketed tablet formulation. These ultraviolet methods are simple, economical and less time consuming as compared to other instrumental methods. The developed methods included the simultaneous equations method and absorbance ratio method. Methanol was used as a dissolving solvent and distilled water was used as a diluent. For the simultaneous equations method, the wavelengths selected were 241 nm (λmax of indapamide) and 224.4 nm (λmax of atenolol) and for absorbance ratio method, the two wavelengths selected were 233.8 nm (isosbestic point) and 224.4 nm (λmax of atenolol). In both approaches, the linearity was proven over concentration ranges of 2-20 µg/ml for indapamide and 10-80 µg/ml for atenolol. The percentage purity in the marketed formulation was found to be 99.79 % for indapamide and 98.57 % for atenolol by simultaneous equations method and 99.56 % for indapamide and 100.0 % for atenolol by absorbance ratio method, which lies within the acceptance criteria i.e., 95 %-105 %. The methods were validated as per the International Council for Harmonisation guidelines and were found to be linear, precise, accurate, sensitive and robust and hence can be used for the estimation of indapamide and atenolol simultaneously in tablet formulation. [ABSTRACT FROM AUTHOR]

The article addresses the problem of the presence of selected pharmaceuticals in waters by determining the state of scientific knowledge. The sources of drug residues in the aquatic environment were characterized and the most important information was collected on the toxicity measures of the most commonly used drugs, including NLPZ: (1) non-steroidal analgesics and antipyretics (diclofenac, ibuprofen, phenazone, acetaminophen, propyphenazone, indomethacin, ketoprofen, pentoxifylline, and phenacetin), (2) pharmaceuticals used to reduce blood lipid levels (bezafibrate, fenofibrate, gemfibrozil), (3) drugs used in cardiac conditions, in particular those used to lower blood pressure and treat arrhythmia (atenolol, sotalol, metoprolol), (4) antibiotics (trimethoprim, clarithromycin, amoxicillin, sulfamethoxazole, piperacillin, erythromycin, sulfadimidine, dehydrate-erythromycin, 4N-Acetylsulfamethoxazol), (5)drugs used to treat rheumatoid arthritis (naproxen, fenoprofen), and (6) anticonvulsants, drugs used in neuropathic disorders and tranquilisers (carbamazepine, diazepam, primidone, oxazepam, temazepam). The authors reviewed research papers dealing with the indicated issue, taking into account: (1) research on the presence of pharmaceuticals in water, (2) studies on the health and environmental risk of drinking water for the presence of drug residues and their mixtures, (3) research on the effectiveness of water treatment in terms of pharmaceuticals. Gaps in scientific knowledge have been demonstrated, which are a hint for the directions of future research work. [ABSTRACT FROM AUTHOR]

In small populations and scattered communities, wastewater treatment through vegetation filters (VFs), a nature-based solution, has proved to be feasible, especially for nutrient and organic matter removal. However, the presence of pharmaceuticals in wastewater and their potential to infiltrate through the vadose zone and reach groundwater is a drawback in the evaluation of VF performances. Soil amended with readily labile carbon sources, such as woodchips, enhances microbial activity and sorption processes, which could improve pharmaceutical attenuation in VFs. The present study aims to assess if woodchip amendments to a VF's soil are able to abate concentrations of selected pharmaceuticals in the infiltrating water by quantitatively describing the occurring processes through reactive transport modelling. Thus, a column experiment using soil collected from an operating VF and poplar woodchips was conducted, alongside a column containing only soil used as reference. The pharmaceuticals acetaminophen, naproxen, atenolol, caffeine, carbamazepine, ketoprofen and sulfamethoxazole were applied daily to the column inlet, mimicking a real irrigation pattern and periodically measured in the effluent. Ketoprofen was the only injected pharmaceutical that reached the column outlet of both systems within the experimental timeframe. The absence of acetaminophen, atenolol, caffeine, carbamazepine, naproxen and sulfamethoxazole in both column outlets indicates that they were attenuated even without woodchips. However, the presence of 10,11-epoxy carbamazepine and atenolol acid as transformation products (TPs) suggests that incomplete degradation also occurs and that the effect of the amendment on the infiltration of TPs is compound-specific. Modelling allowed us to generate breakthrough curves of ketoprofen in both columns and to obtain transport parameters during infiltration. Woodchip-amended columns exhibited Kd and μw values from one to two orders of magnitude higher compared to soil column. This augmentation of sorption and biodegradation processes significantly enhanced the removal of ketoprofen to over 96%. [ABSTRACT FROM AUTHOR]

Nebivolol could prevent dysfunction in patients suffering myocardial ischemia. However, influence of hyperthyroidism is not known. Consequences and mechanisms of nebivolol treatment were investigated in isolated hearts from euthyroid (EuT) and hyperthyroid (HpT) rats. Rats were orally treated during 1 week with 20 mg/kg/day nebivolol (O-Neb), 30 mg/kg/day atenolol (O-Ate), or not treated (C). Isolated perfused hearts were exposed to global ischemia and reperfusion (I/R) inside a flow calorimeter. Left diastolic ventricular pressure, developed contractile pressure (P), and total heat rate (Ht) were continuously measured, while infarct size was measured after 2-h R. EuT-C and HpT-C hearts developed similarly low post-ischemic contractile recovery and economy (P/Ht). Nebivolol totally prevented dysfunction and reduced infarction size in EuT hearts, but partially improved recovery in HpT rat hearts. Contrarily, oral atenolol totally prevented dysfunction in HpT hearts but partially in EuT hearts. Nebivolol effects were reversed by perfusing L-NAME in both conditions, but partially reduced by aminoguanidine in HpT. However, L-NAME increased P and P/Ht recoveries in EuT-C and HpT-C rat hearts, as well as melatonin. Oral nebivolol prevented post-ischemic dysfunction and infarction in EuT hearts due to adrenergic β1 blockade and activation of iNOS and/or eNOS, but the effect was attenuated in HpT hearts by excessive iNOS-dependent nitrosative pathways. [ABSTRACT FROM AUTHOR]

Tamsulosin, a selective α1-adrenoceptor antagonist, is primarily approved for managing benign prostatic hyperplasia. Its off-label application in facilitating the spontaneous passage of ureteral stones, particularly in cases of renal colic, has gained traction in recent years. This report details a rare adverse effect of Tamsulosin observed in a young woman who was concurrently receiving atenolol for primary hypertension and was prescribed Tamsulosin following an episode of renal colic. Remarkably, after three doses, she developed severe constipation, a condition that necessitated manual interventions for resolution. Upon discontinuing Tamsulosin, her bowel function normalized. Given the localization of α1-adrenoceptors in the smooth muscles of intestinal sphincters, it is postulated that Tamsulosin's action, potentially compounded by atenolol's effects, contributed to this adverse reaction. This case underscores the importance of cautious prescribing and monitoring when utilizing Tamsulosin in contexts outside its primary indication. It highlights the intricate interplay between pharmacodynamics and individual patient factors in clinical settings.

Abstract Background Cardiovascular (CV) disease is a leading cause of death in breast cancer (BC) patients due to the increased age and treatments. While individual β-blockers have been investigated to manage CV complications, various β-blockers have not been compared for their effects on CV death in this population. We aimed to compare CV mortality in older BC patients taking one of the commonly used β-blockers. Methods This retrospective cohort study was conducted using the Surveillance, Epidemiology and End Results (SEER) - Medicare data (2010–2015). Patients of age 66 years or older at BC diagnosis receiving metoprolol, atenolol, or carvedilol monotherapy were included. The competing risk regression model was used to determine the risk of CV mortality in the three β-blocker groups. The multivariable model was adjusted for demographic and clinical covariates. The adjusted hazard ratio (HR) and 95% confidence intervals (CI) were reported for the risk of CV mortality. Results The study cohort included 6,540 patients of which 55% were metoprolol users, 30% were atenolol users, and 15% were carvedilol users. Metoprolol was associated with a 37% reduced risk of CV mortality (P = 0.03) compared to carvedilol after adjusting for the covariates (HR = 0.63; 95% CI 0.41–0.96). No significant difference in the risk of CV mortality between atenolol and carvedilol users was observed (HR = 0.74; 95% CI 0.44–1.22). Conclusions Our findings suggest that metoprolol is associated with a reduced risk of CV mortality in BC patients. Future studies are needed to confirm these findings and understand the mechanism of action.

The article describes the case of a 34-year-old man with a four-day history of fever and abnormal behavior in the form of irritability, easily being annoyed, and restlessness. A diagnosis of febrile encephalopathy was made and tests were performed to identify the cause. He received antibiotics, atenolol, pantoprazole, and clonazepam but did not improve his condition and he became drowsy and less communicative. The patient met the criteria for serotonin syndrome and responded to cyproheptadine.

Maltodextrins are products of starch hydrolysis that can be processed into dry fibres through electrospinning and subsequently cured via mild thermal treatment to obtain nonwoven cross-linked polysaccharide-based mats. The sustainability of the process and the bioderived nature make this class of materials suitable candidates to be studied as renewable sorbents for the removal of contaminants from water. In this work, electrospinning of water solutions containing 50% wt. of commercial maltodextrin (Glucidex 2®) and 16.6% wt. of citric acid was carried out at 1.2 mL/h flow and 30 kV applied voltage, followed by thermal curing at 180 °C of the dry fibres produced to obtain cross-linked mats. Well-defined fibres with a mean diameter of 1.64 ± 0.35 µm were successfully obtained and characterised by scanning electron microscopy, thermogravimetric analysis, and attenuated total reflectance Fourier transform infrared spectroscopy. Afterwards, a series of sorption tests were conducted to evaluate the effectiveness of the mats in removing atenolol from water. The results of the batch tests followed by HPLC-UV/Vis showed high sorption rates, with over 90% of the atenolol removed, and a maximum removal capacity of 7 mg/g. Furthermore, continuous fixed-bed sorption tests proved the positive interaction between the polymers and atenolol. [ABSTRACT FROM AUTHOR]

The focus of this review article was to outline the sources, pathways, effects, occurrence, and spatial distribution of the most prescribed pharmaceuticals in wastewater and receiving waters of South Africa. Google Scholar, Web of Science, and Scopus were used to gather data from different regions. A zone-wise classification method was used to determine the spatial distribution and data deficiencies in different regions of South Africa. This review revealed that over 100 pharmaceutical compounds have been reported in South Africa's various water sources and wastewater, with most studies and highest concentrations being documented in Gauteng and Kwa-Zulu Natal. The pharmaceutical concentration in water samples ranged from ng/L to µg/L. Aspirin, ketoprofen, diclofenac, ibuprofen, naproxen, erythromycin, tetracycline, sulfamethoxazole, acetaminophen, streptomycin, ciprofloxacin, ampicillin, carbamazepine, atenolol, pindolol, efavirenz, and zidovudine residues were among the frequently detected pharmaceutical residues in water bodies and wastewaters of South Africa. Based on the spatial distribution data, Gauteng has the highest number of pharmaceuticals (108) detected in waste and surface water, with the Northern Cape having no monitoring evidence. Therefore, to precisely ascertain the geographical distribution of pharmaceutical contaminants in South Africa, this review recommends that further research be carried out to track their occurrence in aquatic environments and WWTP, especially in isolated regions like Limpopo. [ABSTRACT FROM AUTHOR]

Objective: This study examined the rates and persistence of clozapine-induced tachycardia and heart-rate differences in patients treated with β-blockers in the largest sample of patients with a psychotic disorder to date. Method: An audit of medical files for 101 patients who attended a clozapine community clinic and analysis of monthly measurements of resting heart rates. Results: 51% met the clinical criteria for tachycardia. Heart rates were stable over time. β-blockers were associated with small but significant reductions in heart rates. Conclusion: The cardiovascular risks of clozapine are often overlooked. β-blockers are useful in lowering heart rates but they may be insufficient to reduce cardiac risk. [ABSTRACT FROM AUTHOR]

A simple, accurate and economical UV spectroscopic method has been developed for the simultaneous estimation of olopatadine hydrochloride and montelukast sodium. The developed method is based on the determination of the two drugs using UV absorbance correction principle. The wavelengths chosen for analysis were 352 nm for montelukast sodium (as absorbance due to the other drug was nil at this wavelength) and 298.5 nm for olopatadine hydrochloride (corrected for absorbance due to montelukast sodium) with water as diluent. The Beer-Lambert's range for the two drugs was found to be 2-100 μg mL-1 at 298.5 nm and 2-70 μg mL-1 at 352 nm for montelukast sodium with r2 of ≥ 0.990. The developed method was validated as per ICH guidelines and the percentage assay results were within acceptable limits. The developed method can thus be successfully used for the regular analysis of olopatadine hydrochloride and montelukast sodium in bulk and in combination. [ABSTRACT FROM AUTHOR]

Objective To observe the clinical efficacy and complications of β receptor blockers for infantile hemangioma (IH) and observe the effect on growth and development during treatment. Methods From January 2017 to may 2022, 33 IH children were recruited. They were randomized into two groups of propranolol (n=22) and atenolol (n=11) according to parental wishes. No significant inter-group differences existed in age, gender, location or type (P>0.05). The former group received an oral dose of non-selective propranolol 1.5-2 mg·kg-1·d-1. And the latter group was prescribed with atenolol at 0.5 mg·kg-1·d-1 in the first week and then 1 mg·kg-1·d-1. During monthly follow-ups, the changes of clinical manifestations such as tumor color, size, texture and the complications were recorded. Color Doppler ultrasound was performed for measuring tumor volume and evaluating growth and development. Results There was nostatistically significant difference in the age, gender, Location, and type of initial diagnosis between the two groups of chidren(P > 0.05). The effective rate of both groups was 100%. No statistically significant reduction occurred in tumor volume in neither groups at Month 1, 5-6 and 10-12 post-treatment (P>0.05). Adverse reactions of drug dosing occurred in propranolol group (5/22, 22.7%) with respiratory symptoms, fretting or sleep disorder and atenolol group(2/11, 18.2%)with fretting or sleep disorder. No other serious adverse reactions occurred. No abnormality was found in physical development of neither groups during follow-ups. The developmental quotient of two groups did not differ significantly at Month 1/3/6/9 post-dosing (P>0.05). Conclusions The efficacies and complications of propranolol and atenolol are comparable for infantile hemangioma. No significant inter-group difference exists in growth and development during treatment. Regarding the impact of respiratory tract, atenolol may replace propranolol for infantile hemangiomas. [ABSTRACT FROM AUTHOR]

Photocatalysis is a promising technology for wastewater treatment. It is of great significance to find catalysts with high photoactivity. In this paper, a catalyst with high photocatalytic degradation efficiency to organic wastewater, carbon nitride modified by graphene quantum dots (SCN-GQDX), is prepared by supramolecular self-assembly thermal polycondensation method and doping graphene quantum dots (GQDs). The results show that SCN-GQD0.5 has the best catalytic performance, and its photocatalytic degradation efficiency to organic pollutants can reach 86% and still remains above 83% after five cycles, which shows the modified carbon nitride has high catalytic efficiency and stability. In a word, SCN-GQDX is a highly efficient, non-toxic and stable photocatalyst for organic pollutants in wastewater. [ABSTRACT FROM AUTHOR]

A new approach for the determination of atenolol (ATN) at a graphite polyurethane composite electrode (GPUE) modified with electrodeposited nickel(II) nanoparticles electrochemically pretreated in alkaline medium (GPUE-NiNP) is reported. The electrodeposition of NiNP on the GPUE surface was performed by 5 scans in cyclic voltammetry between 0.0 to −1.5 V (vs. SCE) and scan rate of 20 mV s−1 in a 0.05 mol L−1 NiSO4 and 0.32 mol L−1 H3BO3 solution at pH 5. After deposition, the GPUE-NiNP was submitted to an electrochemical pretreatment in 0.50 mol L−1 NaOH by cyclic voltammetry at 100 mV s−1. The best results were obtained after 50 cycles at 100 mV s−1. Quantitative measurements at GPUE-NiNP were performed using differential pulse voltammetry (DPV) in pH 11 universal buffer. Atenolol promotes a decrease in the nickel oxide signals probably due to a complexation of the analyte with free Ni2+ in solution. Thus, the analyte was quantified by the signal suppression and an analytical curve was obtained at the GPUE-NiNP using the optimized conditions for 1.0 to 100 x 10−8 mol L−1 atenolol between 1.0 and 0.0 V (vs. SCE) with a linear range between 2.0 x 10−8 and 1.0 x 10−7 mol L−1 and a limit of detection of 3.47 x 10−9 mol L−1 with R = 0.9995 for GPUE-NiNP. The procedure was applied to three commercial pharmaceutical formulations with recoveries between 99.5 and 100.7% and agreed with a comparative HPLC procedure within 95% confidence level according to the Student's t-test. [ABSTRACT FROM AUTHOR]

Aim: The purpose of the study was development and evaluation of Atenolol loaded microsponge in situ gel for the management of ocular hypertension, glaucoma. Materials and Methods: The microsponges were prepared by modified oil in oil emulsion solvent diffusion method. The polymers used for fabrication of microsponges include Ethyl Cellulose and Eudtagit RL-100. Results: The results of particle reveals that the particle size varies from 7.33 to 9.76µm, percentage yield ranges from 59.98 to 81.22, entrapment efficiency (%) 58.23 to 80.56 and drug content (%) varies from 54.12 to 82.89. Further, the microsponges were loaded in in situ gel. The in situ gel was fabricated by using Poloxamer 407 and HPMC K4M polymers. The microsponges loaded in situ gel was evaluated for different parameters like pH, viscosity, gelling capacity, gelation temperature and drug release study. The pH varies from 6.83 to 7.43, viscosity ranges from 7421 to 15623 cp, gelation temperature ranges from 37.14 to38.22°C while the drug release ranges from 62.52 to 83.32%. At last, the stability study report indicated that the developed drug loaded microsponge in situ gel were physically and chemically stable over a period of three months. Sterility testing was conducted in the optimized formulations as per Indian Pharmacopoeia. The studies reveal that there was no sign of growth of microorganism. Conclusion: Atenolol loaded microsponge loaded in situ gel can effectively treat Glaucoma and improve the patient compliance. [ABSTRACT FROM AUTHOR]

Copyright of Archives of the Turkish Society of Cardiology / Türk Kardiyoloji Derneği Arşivi is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

This study aimed to assess the dynamic simulation models provided by Aspen adsorption (ASPAD) and artificial neural network (ANN) in understanding the adsorption behavior of atenolol (ATN) on gasified Glyricidia sepium woodchips activated carbon (GGSWAC) within fixed bed columns for wastewater treatment. The findings demonstrated that increasing the bed height from 1 to 3 cm extended breakthrough and exhaustion times while enhancing adsorption capacity. Conversely, higher initial ATN concentrations resulted in shorter breakthrough and exhaustion times but increased adsorption capacity. Elevated influent flow rates reduced breakthrough and exhaustion times while maintaining constant adsorption capacity. The ASPAD software demonstrated competence in accurately modeling the crucial exhaustion points. However, there is room for enhancement in forecasting breakthrough times, as it exhibited deviations ranging from 6.52 to 239.53% when compared to the actual experimental data. ANN models in both MATLAB and Python demonstrated precise predictive abilities, with the Python model (R2 = 0.985) outperforming the MATLAB model (R2 = 0.9691). The Python ANN also exhibited superior fitting performance with lower MSE and MAE. The most influential factor was the initial ATN concentration (28.96%), followed by bed height (26.39%), influent flow rate (22.43%), and total effluent time (22.22%). The findings of this study offer an extensive comprehension of breakthrough patterns and enable accurate forecasts of column performance. [ABSTRACT FROM AUTHOR]

The limited availability of pharmaceutical formulations tailored for cardiovascular diseases in both pediatric and geriatric populations generates the need for compounded dosage forms to guarantee precise dosing and medication adherence. This study aimed to analyze the physicochemical properties and stability of formulations of atenolol and enalapril maleate prepared with a proprietary oral vehicle, SuspendIt®. To this end, palatability, injectability, pH, rheological behavior, and physical, microbiological, and chemical stability over a 180-day storage period at 25 °C and 5 °C were evaluated. Injectability tests confirmed the suitable use of both formulations for administration through enteral feeding tubes. By using a potentiometric electronic tongue, it was confirmed that the SuspendIt® vehicle effectively served as a bitter-blocking strategy for atenolol and enalapril maleate. Adequate stability throughout the storage period was confirmed in terms of the mechanical properties, pH, and effectiveness of the preservative system. The atenolol concentration remained above 90% of the initial amount, while the concentration of enalapril maleate decreased to 88% after 90 days of storage at 25 °C. In summary, the atenolol formulation maintained suitable chemical, physical, and microbiological stability after 180 days at both storage temperatures, while the enalapril maleate formulation remained stable up to 60 days at 25 °C and for 180 days at 5 °C.